Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Generic Makers Need More Time to Meet Higher Target: JGA Leader
May 27, 2015
- 3 Companies Received Guidance, 2 Received Warnings in FY2014 due to Fair Competition Code Violations: Maker’s FTC
May 27, 2015
- JPMA Chief Fires at Proposed 80-90% Generic Share Target
May 27, 2015
- JPMA Official Praises Sakigake System as “Ground-Breaking,” Expresses Concern Over Impact of Compassionate Use System
May 12, 2015
- “Stable Supply System” Key for Adopting Generics at Insurance Pharmacies: JGA Survey
May 11, 2015
- JPMA Preparing “Action Guidelines” to Ensure Greater Transparency
April 24, 2015
- Expert Warns against Research-Driven Makers’ Foray into Indian Market
April 22, 2015
- JPMA to Step Up Calls for Biowaivers Using IVIVC
April 21, 2015
- MHLW to Inquire with Drug Makers about Payments to PAFSC Members
April 17, 2015
- Japan Drug Costs to Remain Flat thru 2025, No Annual Price Cuts Necessary: EFPIA
April 15, 2015
- APAC Approves “Good Submission Practice” Guidelines Aimed at Reducing Time to Approval in Asia
April 13, 2015
- JPA Vice President Disagrees with Exclusion of OTC-Like Drugs from Insurance Coverage
April 13, 2015
- JPMA to Closely Watch Clinical Research Bill to Decide Whether to Review All Ads
April 6, 2015
- October-December Generic Share Down 1.3 Points from Prior Qtr: JGA
March 27, 2015
- 15 Drug Makers to Jointly Purchase 150,000 Compounds for Compound Libraries Over 5-Year Period Starting in FY2015
March 27, 2015
- 1st Generation Poultices “Just One Example” for Proposal to Scrap Health Coverage for OTC-Like Drugs: Shirakawa
March 26, 2015
- Applying Uniform Pricing Rule to Unprofitable but Essential Drugs Difficult: Kenporen Veep
March 26, 2015
- JPMA to Begin Operating New Statistical Drug Database in FY2015
March 23, 2015
- JPMA Suspends Hasegawa’s Veep Duties for Another 2 Months over CASE-J
March 20, 2015
- FPMAJ Renews Call for Changing NHI Pricing Rules for Unprofitable Drugs with Great Medical Needs
March 20, 2015
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…